Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 10
2005 5
2006 5
2007 12
2008 6
2009 7
2010 14
2011 8
2012 13
2013 6
2014 11
2015 4
2016 11
2017 11
2018 6
2019 5
2020 13
2021 11
2022 25
2023 15

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Anti CD38 monoclonal antibodies for multiple myeloma treatment.
Gozzetti A, Ciofini S, Simoncelli M, Santoni A, Pacelli P, Raspadori D, Bocchia M. Gozzetti A, et al. Hum Vaccin Immunother. 2022 Nov 30;18(5):2052658. doi: 10.1080/21645515.2022.2052658. Epub 2022 Apr 11. Hum Vaccin Immunother. 2022. PMID: 35404740 Free PMC article. Review.
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
Dimopoulos MA, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison SJ, Kastritis E, Garderet L, Gozzetti A, van de Donk NWCJ, Weisel KC, Badros AZ, Beksac M, Hillengass J, Mohty M, Ho PJ, Ntanasis-Stathopoulos I, Mateos MV, Richardson P, Blade J, Moreau P, San-Miguel J, Munshi N, Rajkumar SV, Durie BGM, Ludwig H, Terpos E; International Myeloma Working Group. Dimopoulos MA, et al. Among authors: gozzetti a. Lancet Oncol. 2023 Jul;24(7):e293-e311. doi: 10.1016/S1470-2045(23)00223-1. Lancet Oncol. 2023. PMID: 37414019 Review.
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. Grever MR, et al. Among authors: gozzetti a. Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30. Blood. 2017. PMID: 27903528 Free PMC article.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
Mateos MV, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J. Mateos MV, et al. Among authors: gozzetti a. Blood Cancer J. 2020 Oct 16;10(10):102. doi: 10.1038/s41408-020-00366-3. Blood Cancer J. 2020. PMID: 33067414 Free PMC article.
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors.
Gozzetti A, Guarnieri A, Zamagni E, Zakharova E, Coriu D, Bittrich M, Pika T, Tovar N, Schutz N, Ciofini S, Peña C, Rocchi S, Rassner M, Avivi I, Waszczuk-Gajda A, Chhabra S, Usnarska-Zubkiewicz L, González-Calle V, Mateos MV, Bocchia M, Bigi F, Füllgraf H, Bhasin-Chhabra B, Gentile M, Davila J, Vesole DH, Cavo M, Thapa B, Crusoe E, Einsele H, Legiec W, Charliński G, Jurczyszyn A. Gozzetti A, et al. Am J Hematol. 2022 Jul;97(7):877-884. doi: 10.1002/ajh.26566. Epub 2022 Apr 20. Am J Hematol. 2022. PMID: 35389534 Free PMC article.
Commentary.
Gozzetti A. Gozzetti A. J Neurosci Rural Pract. 2013 Oct;4(4):448. J Neurosci Rural Pract. 2013. PMID: 24347955 Free PMC article. No abstract available.
Editorial: Molecular Mechanisms of Multiple Myeloma.
Gozzetti A, Kok CH, Li CF. Gozzetti A, et al. Front Oncol. 2022 Mar 10;12:870123. doi: 10.3389/fonc.2022.870123. eCollection 2022. Front Oncol. 2022. PMID: 35359371 Free PMC article. No abstract available.
Anti-BCMA novel therapies for multiple myeloma.
Sammartano V, Franceschini M, Fredducci S, Caroni F, Ciofini S, Pacelli P, Bocchia M, Gozzetti A. Sammartano V, et al. Among authors: gozzetti a. Cancer Drug Resist. 2023 Mar 22;6(1):169-181. doi: 10.20517/cdr.2022.138. eCollection 2023. Cancer Drug Resist. 2023. PMID: 37065871 Free PMC article. Review.
Hyperlipidemic myeloma.
Gozzetti A, Defina M, Bocchia M, Lauria F. Gozzetti A, et al. Ann Hematol. 2010 Sep;89(9):939-40. doi: 10.1007/s00277-010-0905-5. Epub 2010 Feb 2. Ann Hematol. 2010. PMID: 20127090 No abstract available.
183 results